Skip to main content

Cipher Pharmaceuticals Inc.

corporate_fare Company Profile

Cipher Pharmaceuticals Inc.

CPHRF·OTC·Healthcare·CIK 0001358575

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company based in Canada. The company provides a range of pharmaceutical products. Its offerings include Epuris (isotretinoin), an oral retinoid for severe nodular, inflammatory, conglobate, and recalcitrant acne. It also offers Actikerall, a topical solution for Grade I/II hyperkeratotic actinic keratosis of the face, forehead, and balding scalp, and Vaniqa, a topical cream to slow unwanted facial hair growth in women. Other products include Durela, an opioid analgesic for moderate to moderately severe pain in adults; Brinavess for rapid conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor for acute coronary syndrome; and Natroba for topical treatment of head lice and scabies infestations in adult and pediatric patients. Cipher Pharmaceuticals also has licensed products such as Absorica, an oral retinoid for severe nodular, inflammatory, conglobate, and recalcitrant acne; Conzip, an opioid agonist for moderate to moderately severe chronic pain in adults; and Lipofen, an adjunctive therapy to diet for reducing elevated LDL-C, total-C, triglycerides, and Apo B, and increasing HDL-C. The company's pipeline includes piclidenoson CF-101 for moderate to severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical terbinafine formulation in phase 3 clinical trials for onychomycosis; and DTR-001, a tattoo removal cream. The company was founded in 2000 and is headquartered in Mississauga, Canada.

Cipher Pharmaceuticals Inc. (OTC:CPHRF) is a publicly traded company in the Healthcare sector. Wiseek has independently scored 1 item for CPHRF at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-03-12, rated 9/10.

Recent high-impact activity:

  • Cipher Pharmaceuticals Reports Record 2025 Revenue and Earnings, Eyes Future Acquisitions

Short Interest & Short Volume

97.69 days to cover

FINRA reported short interest of 223,521 shares in CPHRF as of the October 30, 2026 settlement, a 0.3% decrease from the prior period — about 97.7 days to cover at its recent average daily volume. On November 20, 2026, 8.9% of CPHRF volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)223,521 shares as of October 30, 2026
Change vs prior period▼ 0.3%
Days to cover97.69 at avg daily volume of 2,288
Daily short volume (FINRA facilities)8.9% of 11,194 shares on November 20, 2026
5-day average short volume11.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

No longer listed

CPHRF (Cipher Pharmaceuticals Inc.) is no longer listed on a major US exchange, so Wiseek no longer shows market data for this symbol. It last appeared on NASDAQ. The filings and coverage below remain available as an archive.

feed CPHRF - Latest Insights

CPHRF
Mar 12, 2026, 5:00 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets